The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Purification and Characterization of Mouse Soluble Receptor for Advanced Glycation End Products (sRAGE)
Open accessAbstract
The receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily of cell surface proteins that has been implicated as a progression factor in a number of pathologic conditions from chronic inflammation to cancer to Alzheimer's disease. In such conditions, RAGE acts to facilitate pathogenic processes. Its secreted isoform, soluble RAGE or sRAGE, has the ability to prevent RAGE signaling by acting as a decoy. sRAGE has been used successfully in animal models of a range of diseases to antagonize RAGE-mediated pathologic processes. In humans, sRAGE results from alternative splicing of RAGE mRNA. This study was aimed to determine whether the same holds true for mouse sRAGE and, in addition, to biochemically characterize mouse sRAGE. The biochemical characteristics examined include glycosylation and disulfide patterns. In addition, sRAGE was found to bind heparin, which may mediate its distribution in the extracellular matrix and cell surfaces of tissues. Finally, our data indicated that sRAGE in the mouse is likely produced by carboxyl-terminal truncation, in contrast to the alternative splicing mechanism reported in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases
Taguchi, A., Blood, D. C., del Toro, G., Canet, A., Lee, D. C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., et al. (2000) · Nature · doi:10.1038/35012626 · Cited by 1,217
YONEKURA, H., YAMAMOTO, Y., SAKURAI, S., PETROVA, R. G., ABEDIN, M. J., LI, H., YASUI, K., TAKEUCHI, M., MAKITA, Z., TAKASAWA, S., et al. (2003) · Biochemical Journal · doi:10.1042/bj20021371 · Cited by 716
Li, J., & Schmidt, A. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.26.16498 · Cited by 525
Cited by
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
Lotze, M. T., & Tracey, K. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1594 · Cited by 2,487
Understanding RAGE, the receptor for advanced glycation end products
Bierhaus, A., Humpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, D. M., & Nawroth, P. P. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0688-7 · Cited by 1,297
“In mice, however, these truncated RAGE isoforms are likely produced by carboxyl-terminal truncation [19].”
BackgroundLotze, M. T., Zeh, H. J., Rubartelli, A., Sparvero, L. J., Amoscato, A. A., Washburn, N. R., DeVera, M. E., Liang, X., Tör, M., & Billiar, T. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00579.x · Cited by 641
Sparvero, L. J., Asafu-Adjei, D., Kang, R., Tang, D., Amin, N., Im, J., Rutledge, R., Lin, B., Amoscato, A. A., Zeh, H. J., et al. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-17 · Cited by 622
Raucci, A., Cugusi, S., Antonelli, A., Barabino, S. M., Monti, L., Bierhaus, A., Reiss, K., Saftig, P., & Bianchi, M. E. (2008) · The FASEB Journal · doi:10.1096/fj.08-109033 · Cited by 555
High-mobility group box 1 and cancer
Tang, D., Kang, R., Zeh III, H. J., & Lotze, M. T. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.11.014 · Cited by 512
Binding of S100 proteins to RAGE: An update
Leclerc, E., Fritz, G., Vetter, S. W., & Heizmann, C. W. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.11.016 · Cited by 489
Receptor for Advanced Glycation End-Products Is a Marker of Type I Cell Injury in Acute Lung Injury
Uchida, T., Shirasawa, M., Ware, L. B., Kojima, K., Hata, Y., Makita, K., Mednick, G., Matthay, Z. A., & Matthay, M. A. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200509-1477oc · Cited by 467
Falcone, C., Emanuele, E., D’Angelo, A., Buzzi, M. P., Belvito, C., Cuccia, M., & Geroldi, D. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000160342.20342.00 · Cited by 377
Masquerader: High Mobility Group Box-1 and Cancer
Ellerman, J. E., Brown, C. K., de Vera, M., Zeh, H. J., Billiar, T., Rubartelli, A., & Lotze, M. T. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1953 · Cited by 355
Rom, S., Zuluaga-Ramirez, V., Gajghate, S., Seliga, A., Winfield, M., Heldt, N. A., Kolpakov, M. A., Bashkirova, Y. V., Sabri, A. K., & Persidsky, Y. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1195-5 · Cited by 330
Zhang, L., Bukulin, M., Kojro, E., Roth, A., Metz, V. V., Fahrenholz, F., Nawroth, P. P., Bierhaus, A., & Postina, R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806948200 · Cited by 284
The Role of Advanced Glycation End Products in Diabetic Vascular Complications
Rhee, S. Y., & Kim, Y. S. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.0105 · Cited by 274
Structural Basis for Pattern Recognition by the Receptor for Advanced Glycation End Products (RAGE)
Xie, J., Reverdatto, S., Frolov, A., Hoffmann, R., Burz, D. S., & Shekhtman, A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801622200 · Cited by 252
The AGE-RAGE Axis: Implications for Age-Associated Arterial Diseases
Senatus, L. M., & Schmidt, A. M. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00187 · Cited by 167
Yamagishi, S.-I., Adachi, H., Nakamura, K., Matsui, T., Jinnouchi, Y., Takenaka, K., Takeuchi, M., Enomoto, M., Furuki, K., Hino, A., et al. (2006) · Metabolism · doi:10.1016/j.metabol.2006.05.007 · Cited by 148
“actions of matrix metalloproteinases [12,13], sRAGE may be positively, rather than inversely, associated with circulating AGEs and may reflect tissue RAGE expression.”
BackgroundEmerging Roles for HMGB1 Protein in Immunity, Inflammation, and Cancer
Ranzato, E., Martinotti, S., & Patrone, M. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s58064 · Cited by 127
“Soluble RAGE acts as a decoy to prevent RAGE signaling and has been used successfully in animal models.(75) Platinating agents such as cisplatin and oxaliplatin have the ability to retain HMGB1 within the nucleus.”
RAGE Signaling in Skeletal Biology
Plotkin, L. I., Essex, A. L., & Davis, H. M. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00499-w · Cited by 54
Methylglyoxal: A Relevant Marker of Disease Activity in Patients with Rheumatoid Arthritis
Knani, I., Bouzidi, H., Zrour, S., Bergaoui, N., Hammami, M., & Kerkeni, M. (2018) · Disease Markers · doi:10.1155/2018/8735926 · Cited by 25
Metadata
- Authors
- Hanford, L. E., Enghild, J. J., Valnickova, Z., Petersen, S. V., Schaefer, L. M., Schaefer, T. M., Reinhart, T. A., & Oury, T. D.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-11
- Volume
- 279
- Issue
- 48
- Pages
- 50019-50024
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2148750797
- Cited by
- 217
- References
- 5
- FWCI
- 9.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.